Reactivation of hepatic EPO synthesis in mice after PHD loss

Science

Volumn 329, Issue 5990, 2010, Pages 407-

  Minamishima, Yoji Andrew ^a   Kaelin Jr , William G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE;

ANEMIA; CYTOGENETICS; GENE EXPRESSION; GENETIC ENGINEERING; PROTEIN; RODENT;

ENZYME ACTIVATION; ERYTHROPOIESIS; HEMATOCRIT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SHORT SURVEY;

ANEMIA; ANIMALS; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMATOCRIT; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY FAILURE, CHRONIC; LIVER; MICE; PROCOLLAGEN-PROLINE DIOXYGENASE; TRANSCRIPTION FACTORS;

MUS;

EID: 77954837178     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1192811     Document Type: Short Survey

References (9)

1. J. Bohlius et al., Lancet 373, 1532 (2009).
2. W. G. Kaelin Jr., P. J. Ratcliffe, Mol. Cell 30, 393 (2008).
3. K. Takeda et al., Blood 111, 3229 (2008).
4. Y. A. Minamishima et al., Blood 111, 3236 (2008).
5. Y. A. Minamishima et al., Mol. Cell. Biol. 29, 5729 (2009).
6. M. Safran et al., Proc. Natl. Acad. Sci. U.S.A. 103, 105 (2006).
7. V. H. Haase, J. N. Glickman, M. Socolovsky, R. Jaenisch, Proc. Natl. Acad. Sci. U.S.A. 98, 1583 (2001).
8. W. Y. Kim et al., EMBO J. 25, 4650 (2006).
9. W.G.K. owns equity in and is a paid consultant for Fibrogen, Incorporated, which is developing PHD inhibitors. W.G.K. is a coinventor on a patent related to clinical use of PHD inhibitors that was licensed to Fibrogen, Incorporated.